Intravitreal crystalline drug delivery for intraocular proliferation diseases.
OBJECTIVE
A long-lasting, slow-release, crystalline antiviral drug delivery system was initially reported using ganciclovir and cyclic cidofovir as the prototype compounds. The present study was undertaken to investigate the feasibility of applying this system to antiproliferative small molecules.


METHODS
The crystalline lipid prodrugs of hexadecyloxypropyl-arabinofuranosylguanine 5'-monophosphate (HDP-P-AraG), hexadecyloxypropyl 5-fluoro-2'-deoxyuridine cyclic 3',5'-monophosphate (HDP-cP-5-F-2dUrd), and hexadecyloxypropyl 5-fluoro-2'-deoxyuridine 5'-monophosphate (HDP-P-5-F-2dUrd) were synthesized from their parent compounds arabinofuranosylguanine (AraG) and 5-fluoro-2'-deoxyuridine (5-F-2dUrd). All three compounds were tested at escalating doses in rabbit eyes. Only one eye of each animal was injected with test compound, and the fellow eye was injected with 5% dextrose as the control. The injected eyes were monitored by slit lamp, a handheld tonometer, indirect ophthalmoscopy, electroretinography (ERG), and histology. The selected doses were used for efficacy study with the rat CNV model or the rabbit PVR model.


RESULTS
The highest nontoxic dose for HDP-P-AraG was 75 microg/eye, and was 70 and 210 microg/eye for HDP-P-5-F-2dUrd and HDP-cP-5-F-2dUrd, respectively. All compounds demonstrated a localized depot of crystalline aggregate in the vitreous with a clear view of vitreous and retina elsewhere. The drug depot of HDP-P-AraG was visible for 4 to 5 weeks; HDP-P-5-F-2dUrd, 8 to 10 weeks; and HDP-cP-5-F-2dUrd longer than 14 weeks. The treatment study showed HDP-P-AraG led to 33% reduction in CNV in the rat (P = 0.015), and HDP-cP-5-F-2dUrd provided 100% prevention of trauma-induced PVR in the rabbit (P = 0.046). The pretreatment study demonstrated a significant protection against intraocular proliferation compared with the 5-FU in a parallel study (P = 0.014).


CONCLUSIONS
The intravitreous injectable lipid prodrugs of AraG and 5-fluoro-2'-deoxyuridine could be long-lasting, slow-release, antiproliferative compounds to treat unwanted intraocular proliferation.
Cheng
Lingyun
L
Jacobs Retina Center at Shiley Eye Center, University of California, San Diego, La Jolla, California, USA. cheng@eyecenter.ucsd.edu
Hostetler
Karl
K
Valiaeva
Nadya
N
Tammewar
Ajay
A
Freeman
William R
WR
Beadle
James
J
Bartsch
Dirk-Uwe
DU
Aldern
Kathy
K
Falkenstein
Iryna
I
D000818:Animals; D001088:Arabinonucleotides / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000633:toxicity; D003460:Crystallization; D003856:Deoxyuracil Nucleotides / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000633:toxicity; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D016503:Drug Delivery Systems; D005451:Fluorescein Angiography; D007267:Injections; D009887:Ophthalmoscopy; D011355:Prodrugs / Q000008:administration & dosage* / Q000737:chemistry / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D011914:Rats, Inbred BN; D012160:Retina / Q000187:drug effects / Q000473:pathology; D015861:Retinal Neovascularization / Q000473:pathology / Q000517:prevention & control*; D014065:Tonometry, Ocular; D018630:Vitreoretinopathy, Proliferative / Q000473:pathology / Q000517:prevention & control*; D014822:Vitreous Body
D001088:Arabinonucleotides; D003856:Deoxyuracil Nucleotides; D011355:Prodrugs; C546831:hexadecyloxypropyl 5'-fluoro-2'-deoxyuridine 5'-monophosphate; C546830:hexadecyloxypropyl 5-fluoro-2'-deoxyuridine cyclic-3',5'-monophosphate; C546829:hexadecyloxypropyl-arabinofuranosylguanine 5'-monophosphate
Antimicrob Agents Chemother. 2002 Aug;46(8):2381-6
12121908
Invest Ophthalmol Vis Sci. 1990 Sep;31(9):1709-16
1698743
Invest Ophthalmol Vis Sci. 2000 May;41(6):1523-32
10798672
Graefes Arch Clin Exp Ophthalmol. 2008 Jan;246(1):161-5
17674019
Eye (Lond). 2006 Mar;20(3):341-6
15905873
Clin Ther. 2007 Sep;29(9):1850-61
18035187
Mol Pharmacol. 2003 Mar;63(3):678-81
12606777
Br J Ophthalmol. 2007 Sep;91(9):1177-82
17475698
Invest Ophthalmol Vis Sci. 1998 Feb;39(2):391-6
9477999
J Ocul Pharmacol Ther. 2003 Apr;19(2):161-9
12804061
Ophthalmic Surg Lasers. 1997 Oct;28(10):823-7
9336775
Ophthalmology. 1995 Mar;102(3):393-400
7891976
Graefes Arch Clin Exp Ophthalmol. 2009 Jan;247(1):1-11
18843500
Br J Ophthalmol. 2004 Sep;88(9):1201-5
15317716
Invest Ophthalmol Vis Sci. 1998 Jan;39(1):212-6
9430566
Invest Ophthalmol Vis Sci. 1999 Jun;40(7):1487-95
10359331
Ophthalmology. 2004 Dec;111(12):2240-5
15582080
J R Coll Surg Edinb. 1989 Dec;34(6):338-9
2628572
Am J Ophthalmol. 1993 Jun 15;115(6):786-91
7685148
Invest Ophthalmol Vis Sci. 2002 Feb;43(2):515-21
11818399
Graefes Arch Clin Exp Ophthalmol. 1995 Jun;233(6):366-70
7672624
Acta Ophthalmol. 2010 May;88(3):358-66
19222399
Graefes Arch Clin Exp Ophthalmol. 1999 Oct;237(10):824-9
10502057
Am J Ophthalmol. 2004 Jun;137(6):1105-15
15183797
Ophthalmology. 1985 Jan;92(1):91-6
3974999
Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4138-44
15505067
Br J Ophthalmol. 2007 Sep;91(9):1122-4
17383993
Am J Ophthalmol. 2008 Feb;145(2):239-248
18222192
Curr Eye Res. 2001 Jan;22(1):74-7
11402382
Oncol Rep. 2007 Feb;17(2):441-6
17203185
Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):746-9
18600535
Am J Ophthalmol. 1997 Jun;123(6):820-31
9535627
Eye (Lond). 2000 Apr;14 ( Pt 2):249-51
10845030
Optometry. 2008 Apr;79(4):197-202
18358999
Am J Ophthalmol. 1983 Jul;96(1):43-51
6869479